777 related articles for article (PubMed ID: 22150560)
1. Oncogenic alterations in papillary thyroid cancers of young patients.
Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
[TBL] [Abstract][Full Text] [Related]
2. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
3. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
[TBL] [Abstract][Full Text] [Related]
4. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
6. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
7. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries.
Vuong HG; Kondo T; Oishi N; Nakazawa T; Mochizuki K; Inoue T; Tahara I; Kasai K; Hirokawa M; Tran TM; Katoh R
Cancer Med; 2016 Aug; 5(8):1883-9. PubMed ID: 27264674
[TBL] [Abstract][Full Text] [Related]
9. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children.
Cordioli MI; Moraes L; Bastos AU; Besson P; Alves MT; Delcelo R; Monte O; Longui C; Cury AN; Cerutti JM
Thyroid; 2017 Feb; 27(2):182-188. PubMed ID: 27849443
[TBL] [Abstract][Full Text] [Related]
10.
Pekova B; Sykorova V; Dvorakova S; Vaclavikova E; Moravcova J; Katra R; Astl J; Vlcek P; Kodetova D; Vcelak J; Bendlova B
Thyroid; 2020 Dec; 30(12):1771-1780. PubMed ID: 32495721
[No Abstract] [Full Text] [Related]
11. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
Zhu XL; Zhou XY; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547
[TBL] [Abstract][Full Text] [Related]
12. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Zou M; Baitei EY; Alzahrani AS; BinHumaid FS; Alkhafaji D; Al-Rijjal RA; Meyer BF; Shi Y
Thyroid; 2014 Aug; 24(8):1256-66. PubMed ID: 24798740
[TBL] [Abstract][Full Text] [Related]
13. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
15. AGK-BRAF gene fusion is a recurrent event in sporadic pediatric thyroid carcinoma.
Cordioli MI; Moraes L; Carvalheira G; Sisdelli L; Alves MT; Delcelo R; Monte O; Longui CA; Cury AN; Cerutti JM
Cancer Med; 2016 Jul; 5(7):1535-41. PubMed ID: 27037835
[TBL] [Abstract][Full Text] [Related]
16. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.
Lee MY; Ku BM; Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Park K; Oh YL; Hong M; Jeong HS; Son YI; Baek CH; Ahn MJ
Cancer Res Treat; 2017 Oct; 49(4):906-914. PubMed ID: 28052655
[TBL] [Abstract][Full Text] [Related]
17. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
[TBL] [Abstract][Full Text] [Related]
18. [BRAF initiating mutations in the papillary thyroid carcinoma].
Rusinek D; Gubała E
Endokrynol Pol; 2006; 57(4):438-44. PubMed ID: 17006850
[TBL] [Abstract][Full Text] [Related]
19. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements.
Sheu SY; Schwertheim S; Worm K; Grabellus F; Schmid KW
Mod Pathol; 2007 Jul; 20(7):779-87. PubMed ID: 17464312
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutations are uncommon in papillary thyroid cancer of young patients.
Penko K; Livezey J; Fenton C; Patel A; Nicholson D; Flora M; Oakley K; Tuttle RM; Francis G
Thyroid; 2005 Apr; 15(4):320-5. PubMed ID: 15876153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
